Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
April 19, 2018 08:00 ET
|
Argos Therapeutics, Inc.
- Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB...
Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
April 02, 2018 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
March 28, 2018 17:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
February 15, 2018 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Obtains Option to License PD1 Checkpoint Inhibitors
February 05, 2018 16:47 ET
|
Argos Therapeutics, Inc.
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on...
Argos Announces One-for-Twenty Reverse Stock Split
January 18, 2018 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.
January 08, 2018 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Provides Financial Update
November 28, 2017 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
November 11, 2017 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Reports Third Quarter 2017 Financial Results and Operational Highlights
November 09, 2017 16:46 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...